Home›Clinical trials›New York

GLP-1 clinical trials in New York: 29 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

29 GLP-1 clinical trials are recruiting at 55 sites in 20 cities across New York. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in New York

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    1 site in New York

    • Naomi Berrie Diabetes Center at New York Presbyterian-Columbia University, New York. 212-851-5492

  2. Effects of GH and Lirglutide on AgRP

    Phase 4. Run by Columbia University. Registry number NCT05681299.

    A study of a GLP-1 medicine, liraglutide, in people with growth hormone deficiency.

    Who can join. Adults 18 to 45, have growth hormone deficiency, BMI 19+.

    1 site in New York

    • Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center, New York. 212-305-2254

  3. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in New York

  4. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    1 site in New York

    • University of Rochester Medical Center, Rochester

  5. Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

    Phase 4. Run by Weill Medical College of Cornell University. Registry number NCT07257484.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with breast cancer lose weight.

    Who can join. Adults 18+, women only, have obesity, BMI 27.5+.

    1 site in New York

  6. Incretin Therapies in Obesity-related HFpEF

    Phase 4. Run by Columbia University. Registry number NCT07554638.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with diastolic heart failure lose weight.

    Who can join. Adults 40+, have diastolic heart failure, BMI 30+.

    1 site in New York

    • Columbia University Irving Medical Center (CUIMC) / NewYork Presbyterian Hospital (NYP), New York

  7. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    5 sites in New York
    • Research Foundation of SUNY - University of Buffalo, Buffalo. 716-535-1850
    • IMA Clinical Research Manhattan, New York
    • New York Gastroenterology Associates, New York
    • NYU Langone Health, New York. 646-501-2948
    • Care Access - Yonkers, Yonkers

  8. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    4 sites in New York

  9. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    4 sites in New York

  10. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    3 sites in New York

    • Icahn School of Medicine at Mount Sinai, New York
    • New York Gastroenterology Associates, New York. 212-369-2490
    • Care Access - Yonkers, Yonkers

  11. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    3 sites in New York

    • UBMD Physicians Group - Pediatrics - Conventus, Buffalo
    • SUNY Upstate Medical Univ - Syracuse, Syracuse
    • Advantage Clinical Trials, The Bronx

  12. A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06439277.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    2 sites in New York

    • UBMD Pediatrics, Buffalo
    • SUNY Upstate Medical University, Syracuse

  13. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    2 sites in New York

    • New York Gastroenterology Associates, New York. 212-369-2490
    • Care Access - Yonkers, Yonkers

  14. A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    Phase 3. Run by Vanda Pharmaceuticals. Registry number NCT07446439.

    A study testing whether an investigational medicine from Vanda Pharmaceuticals, tradipitant, can help people reduce nausea and vomiting.

    Who can join. Adults 18 to 65, have nausea and vomiting, BMI 25+.

    2 sites in New York

  15. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Run by Amgen. Registry number NCT07575399.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    2 sites in New York

    • Icahn School of Medicine at Mount Sinai, New York
    • Rochester Clinical Research, Rochester

  16. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in New York

    • UBMD Pediatrics, Buffalo

  17. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Run by Kailera. Registry number NCT07284979.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in New York

    • Kailera Clinical Site, Albany

  18. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in New York

    • Southgate Medical Group, LLP, West Seneca

  19. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in New York

  20. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    4 sites in New York

    • Dent Neurologic Institute, Amherst
    • Velocity Clinical Research, Syracuse, East Syracuse
    • North Suffolk Neurology, Port Jefferson Station
    • Rochester Clinical Research, LLC, Rochester. 585-288-0890
The other 9 studies recruiting in New York

  1. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06897475.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    3 sites in New York

    • NYC Research INC, Long Island City. 516-574-9232
    • Richmond University Medical Center, Staten Island
    • Southgate Medical Group, West Seneca. 716-712-1004

  2. GLP-1R Agonist Treatment for Opioid Use Disorder

    Phase 2. Run by Milton S. Hershey Medical Center. Registry number NCT06548490.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18 to 75, have opioid use disorder, BMI 18+.

    1 site in New York

  3. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT06717698.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    1 site in New York

    • Albany Medical College, Albany

  4. Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

    Phase 2. Run by Washington University School of Medicine. Registry number NCT06976853.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 80, have Crohn's disease, BMI 25+.

    1 site in New York

    • Icahn School of Medicine at Mount Sinai, New York. 212-327-8270

  5. PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm

    Phase 2. Run by Veru Inc. Registry number NCT07446998.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with mobility disability lose weight.

    Who can join. Adults 65+, have obesity or are overweight, BMI 35+.

    1 site in New York

  6. Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

    Phase 2. Run by Johns Hopkins University. Registry number NCT07497399.

    A study of an investigational medicine, NLY01, in people with multiple sclerosis.

    Who can join. Adults 18 to 60, have multiple sclerosis, BMI 27+.

    1 site in New York

  7. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in New York

    • Great Lakes Medical Research, Westfield

  8. A Study of a Weight Loss Intervention in People With Endometrial Cancer

    Phase 1. Run by Memorial Sloan Kettering Cancer Center. Registry number NCT06751589.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with endometrial cancer.

    Who can join. Adults 18+, women only, have endometrial cancer, BMI 25+.

    4 sites in New York

  9. Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy

    Run by State University of New York at Buffalo. Registry number NCT07641361.

    A study in people with type 2 diabetes.

    Who can join. Adults 18 to 60, have obesity or are overweight.

    1 site in New York

    • State University of New York at Buffalo, South Campus, Buffalo. (716) 829 - 5820

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.